Presentation TCT 2017 SENIOR: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs a BMS With Short DAPT in Patients With Coronary Artery Disease Older Than 75 Years Presenter: Robert A. Harrington, Gregg W. Stone, Olivier Varenne November 01, 2017
Presentation TCT 2017 What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis Presenter: Azeem Latib, Gregg W. Stone October 31, 2017
Presentation TCT 2017 FDA Perspectives on Short DAPT IDE Trials Presenter: Mitchell W. Krucoff, P.F. Adrian Magee October 31, 2017
Presentation TCT 2017 The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Standard vs Novel DES and DAPT Duration Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Ajay J. Kirtane October 31, 2017
Presentation TCT 2017 The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Appropriate Patients and DAPT Duration Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Marie-Claude Morice October 31, 2017
Presentation TCT 2017 Rationale and Studies of P2Y12 Inhibitor Monotherapy Presenter: Dominick J. Angiolillo, Marco Valgimigli, Roxana Mehran October 30, 2017
Presentation TCT 2017 Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment Presenter: Dominick J. Angiolillo, Marco Valgimigli, Thomas Engstroem October 30, 2017
Presentation TCT 2017 Switching to and From Cangrelor: When and How? Presenter: Dominick J. Angiolillo, Marco Valgimigli October 30, 2017
Presentation TCT 2017 Switching Between Oral P2Y12 Receptor Inhibitors: When and How? Presenter: Dominick J. Angiolillo, Marco Valgimigli, Matthew J. Price October 30, 2017
Presentation TCT 2017 Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini October 30, 2017
Presentation TCT 2017 Impact of Race and Sex on Platelet Reactivity and Clinical Implications Presenter: Dominick J. Angiolillo, Marco Valgimigli, Ron Waksman October 30, 2017
Presentation TCT 2017 Do We Have Enough Data to Make PCI vs CABG Decisions in Complex CAD Using FFR? Presenter: Fernando Alfonso, Patrick W. Serruys, William F. Fearon October 30, 2017
Presentation TCT 2017 Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies! Presenter: John A. Bittl, Freek W.A. Verheugt, Gennaro Giustino October 30, 2017
Presentation TCT 2017 Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies! Presenter: John A. Bittl, Freek W.A. Verheugt, Dirk Sibbing October 30, 2017
Presentation TCT 2017 DAPT Duration After BVS: Can Evidence-Based Recommendations Be Made? Presenter: John A. Bittl, Freek W.A. Verheugt, Davide Capodanno October 30, 2017
Presentation TCT 2017 Debate: DAPT Duration With Contemporary DES: Short (<1 Year) DAPT for Most ACS Patients! Presenter: John A. Bittl, Freek W.A. Verheugt, Marco Valgimigli October 30, 2017
Presentation TCT 2017 Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More) Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington October 30, 2017
Presentation TCT 2017 Debate: DAPT Duration With Contemporary DES: Prolonged (>1 Year) DAPT for Most ACS Patients! Presenter: John A. Bittl, Freek W.A. Verheugt, Robert W. Yeh October 30, 2017
Presentation TCT 2017 Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients? Presenter: C. Michael Gibson, Stephan Windecker October 30, 2017
Presentation TCT 2017 The CADence Device in the Physiologic Evaluation of Acoustic Coronary Turbulence Presenter: Bernard De Bruyne, Evelyn S. Regar, Joseph Thomas October 30, 2017